

RESEARCH ARTICLE

Open Access

Evidence for a purifying selection acting on the β -lactamase locus in epidemic clones of methicillin-resistant *Staphylococcus aureus*

Catarina Milheiro¹, Ana Portelinha², Ludwig Krippahl³, Hermínia de Lencastre^{1,4} and Duarte C Oliveira^{1,2*}

Abstract

Background: The β -lactamase (*bla*) locus, which confers resistance to penicillins only, may control the transcription of *mecA*, the central element of methicillin resistance, which is embedded in a polymorphic heterologous chromosomal cassette (the *SCCmec* element). In order to assess the eventual correlation between *bla* allotypes and genetic lineages, *SCCmec* types and/or β -lactam resistance phenotypes, the allelic variation on the *bla* locus was evaluated in a representative collection of 54 international epidemic methicillin-resistant *Staphylococcus aureus* (MRSA) clinical strains and, for comparative purposes, also in 24 diverse methicillin-susceptible *S. aureus* (MSSA) strains.

Results: Internal fragments of *blaZ* (the β -lactamase structural gene) were sequenced for all strains. A subset of strains, representative of *blaZ* allotypes, was further characterized by sequencing of internal fragments of the *blaZ* transcriptional regulators, *blaI* and *blaR1*. Thirteen allotypes for *blaZ*, nine for *blaI* and 12 for *blaR1* were found. In a total of 121 unique single-nucleotide polymorphisms (SNP) detected, no frameshift mutations were identified and only one nonsense mutation within *blaZ* was found in a MRSA strain. On average, *blaZ* alleles were more polymorphic among MSSA than in MRSA (14.7 vs 11.4 SNP/allele). Overall, *blaR1* was the most polymorphic gene with an average of 24.8 SNP/allele. No correlation could be established between *bla* allotypes and genetic lineages, *SCCmec* types and/or β -lactam resistance phenotypes. In order to estimate the selection pressure acting on the *bla* locus, the average dN/dS values were computed. In the three genes and in both collections dN/dS ratios were significantly below 1.

Conclusions: The data strongly suggests the existence of a purifying selection to maintain the *bla* locus fully functional even on MRSA strains. Although, this is in agreement with the notion that in most clinical MRSA strains *mecA* gene is under the control of the *bla* regulatory genes, these findings also suggest that the apparently redundant function of *blaZ* gene for the MRSA resistant phenotype is still important for these strains. In addition, the data shows that the sensor-inducer *blaR1* is the primary target for the accumulation of mutations in the *bla* locus, presumably to modulate the response to the presence of β -lactam antibiotic.

Keywords: β -lactamase β -lactam resistance, allelic variation, MSSA, MRSA, *mecA* stabilization

Background

Staphylococcus aureus is a leading cause of nosocomial infections and has recently emerged as a community acquired pathogen [1-3]. *S. aureus* is also a paradigm of adaptive power to antimicrobial chemotherapy, able to develop resistance to virtually all classes of antibiotics

[4]. The acquisition of resistance to β -lactam antibiotics is particularly relevant in clinical terms. Although β -lactams (i.e. penicillin G) were the first class of large-spectrum antibiotics to be introduced into clinical practice, they are still the most widely used due to their high effectiveness, low cost, ease of delivery and minimal side effects [5].

In response to β -lactam chemotherapy, *S. aureus* has sequentially acquired two resistance genes: first *blaZ*, which codes for a β -lactamase and confers resistance to

* Correspondence: dco@fct.unl.pt

¹Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa (ITQB/UNL), Oeiras, Portugal
Full list of author information is available at the end of the article

penicillins only, and then *mecA*, which codes for an extra penicillin-binding protein (PBP2a) with reduced affinity for virtually all β -lactams [6,7]. The transcription of both resistance genes may be controlled by homologous two-component systems consisting on a sensor-inducer (BlaR1 and MecR1) and a repressor (BlaI and MecI). Interestingly, in spite of the cross-resistance to virtually all β -lactams provided by *mecA*, the great majority (> 95%) of contemporary MRSA are still positive for the β -lactamase locus [8]. Moreover, the regulators of *blaZ*, BlaR1 and BlaI, can efficiently induce *mecA* transcription and, do it faster than the “natural” *mecA* regulators, MecR1 and MecI [9,10]. In addition, since many MRSA strains do not have functional *mecI-mecR1* genes due to polymorphisms in the *mecA* regulatory region [11], the *mecA* transcription is presumably under the control of the *blaI-blaR1* genes only. In line with these observations, the presence of the *blaZ* locus has been shown to promote *mecA* acquisition and stabilization [12,13].

In *S. aureus*, the β -lactamase genes may be located in a plasmid or mobilized into the chromosome by transposon Tn552 [14]. In contrast to the diversity of β -lactamase genes found in gram-negative bacteria, all staphylococcal enzymes studied so far are molecular class A serine β -lactamases placed in functional group 2a [8]. The mature form of the enzyme has a molecular mass of 30 kDa, contains 257 amino acids, and is secreted extracellularly [15]. In 1965, Richmond proposed the subdivision of staphylococcal β -lactamases in four serotypes [16], but the structural basis of the distinction between types is still uncertain and no clear relationship between sequence and serotype was found [17]. Interestingly, serotypes were shown to have specific geographic distributions [8], which may suggest a relationship between *bla*-type and genetic lineage. Recently, Olsen *et al* have studied the allelic variation of the *blaZ* gene among several staphylococcal species and 11 BlaZ protein types were identified [14]. The multiple-sequence alignment of those sequence types suggest a separate evolution for plasmid- and chromosomally-encoded *blaZ* and a very low frequency for exchange of the β -lactamase locus between strains and species.

In evolutionary terms, MRSA may be regarded as a recent sub-branch of the *S. aureus* population which has acquired the heterologous chromosomal cassette containing the *mecA* gene - the *SCCmec* element [18]. Molecular epidemiology studies on large collections of MRSA isolates have clearly shown that MRSA has a strong clonal structure and that very few lineages, defined by specific macro-restriction patterns of chromosomal DNA and/or multi-locus sequence types, account for the great proportion of MRSA infections worldwide [19,20]. The clonal structure of MRSA population may result from a “host barrier” for the *mecA*

acquisition, which restricts the number of acquisitions to few more permissive lineages [13,21] and/or from the clonal expansion of previously highly epidemic (MSSA) lineages, which have acquired the *mecA* gene. Recent data based on comparative genomics of MRSA lineages [22-24] supports both mechanisms as it seems that, within the same genetic (epidemic) lineage, *SCCmec* acquisitions may occur continuously at the local level.

In spite of the several lines of evidence suggesting an important role of the *bla* locus in the acquisition, stabilization and regulation of the *mecA* gene, the variability of *bla* genes at the sequence level has never been evaluated among pandemic MRSA lineages. The present study was conducted in order to evaluate the allelic variability of β -lactamase locus in a representative collection of internationally epidemic MRSA clones and also, for comparative purposes, in a diverse collection of methicillin-susceptible *S. aureus* strains (MSSA), in an attempt to make evolutionary correlations between β -lactamase allotypes and β -lactam resistance phenotypes (i.e. MRSA vs MSSA), *SCCmec* types and/or genetic lineages.

Methods

Strain collection

S. aureus strains used in the present study are listed in Tables 1 (MRSA) and 2 (MSSA). All strains have been previously assigned to genetic lineages by Pulse-field gel electrophoresis (PFGE), multi-locus sequence typing (MLST) and protein A sequence typing (*spa* typing). MRSA strains have been additionally characterized in terms of their *SCCmec* types. The presence of a functional β -lactamase locus was confirmed by nitrocefin disks (Sigma) for all strains, in the presence and absence of an inducer (oxacillin at 0.05 mg/L).

Media and growth conditions

Strains were grown overnight at 37°C on tryptic soy agar or tryptic soy broth under aerobic conditions.

DNA isolation

Total DNA was prepared using the Wizard genomic DNA preparation kit (Promega, Madison, WI, USA), according to the manufacturer's recommendations, except for the addition of lysostaphin at 0.5 mg/mL and RNase at 0.3 mg/mL for the lysis step.

DNA amplification and sequencing

The allelic variation on the β -lactamase locus was evaluated by sequencing internal fragments of *blaZ* and its transcriptional regulators, *blaI* and *blaR1*, amplified by PCR. Based on the available sequence at GenBank (accession number: X52734) for Tn552 of *S. aureus*, three pairs of primers were designed as follows (5' → 3'): *blaZ* F1, GAT AAG AGA TTT GCC TAT GC; *blaZ*

Table 1 Characteristics and *bla* locus allotypes of the MRSA strains used in this study

Clonal complex ^{a)}	MLST (ST)	SCCmec type	Strain	Isolation origin	Isolation year	<i>bla</i> locus alleles			Ref.
						<i>blaZ</i>	<i>blaI</i>	<i>blaR1</i>	
8	247	I	E2125	Denmark	1964	1	ND	ND	[30,31]
	247	IA	HPV107	Portugal	1992	1	ND	ND	[30,32]
	247	IA	BK1953	USA	1995	1	ND	ND	[30,33]
	250	I	COL	UK	1965	-			[30]
	250	I	BK793	Egypt	1961	1	1	1	[30,34]
	250	IA	PER34	Spain	1989	1	ND	ND	[30,35]
	239	III	ANS46	Australia	1982	1	1	1	[30,36]
	239	IIIA	HU25	Brazil	1993	1	ND	ND	[30,37]
	239	IIIA	HUSA304	Hungary	1993	1	ND	ND	[30,38]
	239	IIIA	BK2421	USA	1996	1	ND	ND	[30,34]
	8	IVa	USA300	USA	1995-2003	8	4	9	[39,40]
	8	IVa	USA500	USA	1995-2003	1	ND	ND	[39,40]
	8	IVd	BK2529	USA	1996	1	ND	ND	[30,34,39]
	8	IVd	BargII17	USA	1996	1	ND	ND	[30,39,41]
	8	IVE	AR43/3330.1	Ireland	1988-2002	1	1	1	[42]
	8	IVh	GRE120	Greece	1993	1	ND	ND	[39,43]
	72	IVa	USA700	USA	1995-2003	9	-	4	[39,40]
	254	IVh	HAR36	Greece	2002	1	1	1	[39,44]
770	IVb	8/6-3P	Chicago	1996	3	3	6	[45]	
5	5	I	HAR21	Finland	2002	1	ND	ND	[44,46]
	5	I-VAR	PL72	Poland	1991	1	ND	ND	[30,47]
	5	II	N315	Japan	1982	8	4	9	[18]
	5	II	JP1	Japan	1987	8	4	9	[30,48]
	5	II	BK2464	USA	1996	4	6	2	[30,49]
	5	II	USA100	USA	1995-2003	3	3	6	[40,46]
	5	IVa	BM18	USA	1989	4	6	2	[30,39,50]
	5	IVa	FFP311	Portugal	1996	11	1	7	[39,51]
	5	IVa	HSA49	Portugal	1993	11	ND	ND	[39,51]
	5	IVa	HSA74	Portugal	1993	5	3	3	[39,51]
	5	IVc	Q2314	Dallas	1996	3	ND	ND	[52]
	5	IVc	USA800	USA	1995-2003	1	ND	ND	[39,40]
	5	IVc	ARG9	Argentina	1996	11	7	7	[39,51]
	5	IVd	JCSC4469	Japan	1982	1	1	1	[53]
	5	IVg	M03-68	Korea	2003	3	ND	ND	[54]
	5	IV _{NT}	COB3	Colombia	1996	6	5	10	[30,39,55]
	5	VI	HDE288	Portugal	1996	10	-	5	[51,56]
	5	VI	HUC136	Portugal	1995	10	-	5	[51,56]
228	I	HAR40	Belgium	1995	2	3	1	[44,46]	
30	30	IVc	DEN2946	Denmark	2001	1	1	1	[39,57]
	30	IVc	DEN2294	Denmark	2001	1	ND	ND	[39,57]
	36	II	USA200	USA	1995-2003	1	1	1	[40,46]
	36	II	HAR24	Finland	2002	1	ND	ND	[46,47]
22	22	IVh	HAR22	Finland	2002	9	-	4	[39,44]
	22	IVh	HGSA146	Portugal	2003	9	ND	ND	[39,58]
	22	IVh	HGSA163	Portugal	2003	9	ND	ND	[39,58]
45	45	II	USA600	USA	1995-2003	7	4	9	[40,46]
	45	IVa	HAR38	Belgium	1995	6	2	8	[39,44]
	45	V	WIS	Australia	1995	8	ND	ND	[59]
	256	IVa	CA05	Chicago	1999	8	4	9	[45]

Table 1 Characteristics and *bla* locus allotypes of the MRSA strains used in this study (Continued)

1	1	IVa	MW2	USA	1998	6	2	10	[60]
	1	IVa	USA400	USA	1995-2003	6	2	10	[39,40]
80	80	IVc	DEN2949	Denmark	2001	5	3	3	[39,57]
	80	IVc	DEN114	Denmark	2001	5	1	3	[39,57]
Singleton	377	V	HT0184	Greece	2005	6	2	10	[61]
	377	V	HT0826	France	2003	6	ND	ND	[61]

a) Clonal complexes were determined using the E-burst software <http://saureus.mlst.net/>, last accessed on June 04, 2009.
 ND, not determined, -, negative PCR amplification.

R1, GCA TAT GTT ATT GCT TGA CC; *blaI* F1, GCA AGT TGA AAT ATC TAT GG; *blaI* R1, GAA AGG ATC CAT TTT CTG TAC ACT CTC ATC; *blaR1* F1, CAT GAC AAT GAA GTA GAA GC; and *blaR1* R1, CTT ATG ATT CCA TGA CAT ACG. The predicted amplicon sizes were 533 bp for *blaZ*, 484 bp for *blaI* and 537 bp for *blaR1*. PCR was performed in a T1 Thermocycler (Biometra) with the following conditions: 94°C for 4 min; 30 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 1 min; and a final extension at 72°C for 10

min. In each reaction (final volume of 50 µL), 5 ng of chromosomal template, 2.5 U of GoTaq flexi DNA polymerase (Promega), 1× Colorless GoTaq flexi buffer (Promega), 2.5 mM MgCl₂ (Promega), 40 µM of each deoxynucleoside triphosphate (dNTPs mixture, Bioron) and 20 pmol of the forward and reverse primers were used. The amplified fragments were purified using a mix of Exonuclease and SAP enzymes. Sequencing of both strands was performed by MacroGen <http://www.macrogen.com> or STAB Vida <http://www.stabvida.com>.

Table 2 Characteristics and *bla* locus allotypes of MSSA strains used in this study^{a)}

Clonal complex ^{b)}	MLST (ST)	PFGE type	Strain	Origin	Isolation date	<i>bla</i> locus alleles		
						<i>blaZ</i>	<i>blaI</i>	<i>blaR1</i>
1	1	G	IPOP38	Portugal	2001	6	2	10
	188	L	IPOP58	Portugal	2001	6	2	10
	573	M	HSJ109	Portugal	1995	6	2	10
5	5	C	HSA29	Portugal	1992-1993	11	4	7
	5	C	IPOP41	Portugal	2001	6	3	6
8	8	J	IPOP65	Portugal	2001	8	2	ND
	615	E	IPOP32	Portugal	2001	9	1	4
9	9	D	HSJ122	Portugal	1995	12	1	12
10	10	Q	DCC300	Portugal	1996-1997	9	1	5
12	12	X	HSJ130	Portugal	1995	3	3	6
	12	X	Draftees728	Portugal	1996-1997	1	1	1
15	15	K	HSA9	Portugal	1992-1993	6	9	ND
20	20	N	HSA47	Portugal	1992-1993	6	8	11
22	22	T	Draftees721	Portugal	1996-1997	6	3	5
25	25	S	HSA76	Portugal	1992-1993	1	1	1
30	30	A	IPOP37	Portugal	2001	13	1	1
	34	B	IPOP24	Portugal	2001	6	ND	ND
	34	B	IPOP34	Portugal	2001	1	1	ND
	NA	B	IPOP26	Portugal	2001	1	ND	ND
45	45	H	HSA19	Portugal	1992-1993	6	2	10
	45	H	IPOP56	Portugal	2001	6	ND	ND
97	97	P	IPOP50	Portugal	2001	6	ND	ND
121	121	F	IPOP44	Portugal	2001	10	1	5
Singleton	580	R	DCC1185	Portugal	1996-1997	1	1	1

a) MSSA strains have been previously characterized by PFGE and MLST [62].

b) Clonal complexes were determined using the E-burst software <http://saureus.mlst.net/eburst/database.asp>, last accessed on June 04, 2009.
 NA, not available; ND, not determined.

DNA sequences analysis and phylogenetic tree reconstruction

DNA sequencing raw data analysis and multi-sequence alignments were performed using the DNA Star software package (Lasergene). For the multi-sequence alignments, the Clustal W algorithm was used. In order to maximize sequence reads, raw sequences for *blaZ* and *blaR1* were trimmed immediately after the primer sequences keeping the reading frame. As the reverse primer for *blaI* (BlaI R1) is located outside of the coding region, the 3' end of the sequence was trimmed at the end of the coding region. For each gene, allotypes were defined taking as reference the extant sequences of the *bla* locus of Tn552, which were assigned to allotype 1.

Phylogenetic and molecular evolutionary analyses were conducted using *MEGA* version 4 [25] and the resultant phylogenetic trees were obtained using the neighbour-joining (NJ) method with bootstrap analysis using 1000 replicates. In order to evaluate the diversity of the *bla* locus, the Simpson's indexes of diversity (SID) were calculated [26,27] for each locus using the online tool available at <http://www.comparingpartitions.info>. To estimate selection pressure acting on the *bla* locus, we computed the dN/dS ratios for the three genes. The dN/dS ratios were computed for all pairs of alleles with more than 1% substitutions, in order to give an estimate of the divergence of the alleles while excluding those pairs that, being too similar, would give anomalous dN/dS ratios. The dN/dS ratios were computed by Model Averaging, as described in [28] and implemented in the KaKs_Calculator application [29]. This approach fits a set of models by maximum likelihood and then computes the weighted average of the models using a second-order Akaike Information Criterion (AICC).

Nucleotide sequence accession numbers

All nucleotide sequences determined in this study were deposited in Genbank under accession numbers GQ980053-GQ980139 (*blaZ* alleles), GQ980140-GQ980187 (*blaI* alleles) and GQ980188-GQ980236 (*blaR1* alleles).

Results

The allelic variation in the β -lactamase locus (*bla*) was evaluated by sequencing internal fragments of *blaZ*, *blaI* and *blaR1* genes in a representative collection of international epidemic MRSA clones and also, for comparative purposes, in a diverse collection of MSSA strains.

blaZ allelic variability

Thirteen different *blaZ* allotypes were identified within our collection, which comprised 54 MRSA and 24 MSSA (Tables 1 and 2, respectively). Although seven alleles were common to MRSA and MSSA strains, we

found four alleles present in MRSA strains only and two present in MSSA strains only. Moreover, the relative frequencies of each allele were different among MRSA and MSSA strains (Table 3); for instance, *blaZ* allotype 1 was dominant in MRSA strains accounting for 43% (23 out of 54) of the isolates whereas in MSSA it accounted for 21% (5 out of 24) of the isolates, and *blaZ* allotype 6 was present in 11% (6 out of 54) of MRSA but was dominant among MSSA accounting for 46% (11 out of 24) of the isolates. The diversity of *blaZ* gene as measured by the Simpson index of diversity (SID) was higher for the MRSA collection than for MSSA, although not statistically significant due to the partial overlapping of the confidence intervals (SID = 79.18, 95%CI 69.6-88.8 vs SID = 76.09, 95%CI 61.3-90.9, respectively) - see Table 4. Within the length of *blaZ* region analyzed (492 nucleotides), we detected 43 unique single-nucleotide polymorphisms (SNP) and on average, each *blaZ* allele has 12.4 SNP comparing to the prototype *blaZ* sequence of Tn552 (allele 1) - see Tables 3 and 4. Overall, *blaZ* alleles were more variable in MSSA than in MRSA (14.7 and 11.4 SNP/allele, respectively). As illustrated by the allelic frequency distribution per MRSA lineage (Figure 1) or the cluster tree of the thirteen *blaZ* alleles found in our collections (Figure 2), there is no clustering according to genetic lineages, as defined by MLST sequence type and SCC*mec* type, or MSSA/MRSA phenotype; i.e. the same allele could be detected in different genetic lineages or among MRSA and MSSA, and the same lineage could be characterized by several alleles. In addition, there was also no clear clustering of *blaZ* allotypes according to geographic origin or isolation date of the MRSA isolates (see Table 1).

The BlaZ variability in the MRSA and MSSA strains at the protein level was evaluated by comparison of the deduced amino acid sequence of all alleles against the deduced amino acid sequence for the BlaZ of Tn552. Overall, the deduced amino acid sequences of *blaZ* alleles from the MRSA and MSSA strains revealed on average 5.8 silent mutations, 1.8 conservative missense mutations and 4 non-conservative missense mutations per allotype (see Tables 3 and 4). For MRSA strain HAR40, a nonsense mutation at Gln76 was detected which presumably originates a non-functional truncated BlaZ protein. As this strain was positive for the nitrocefin test, the DNA extraction and the *blaZ* sequencing were repeated and the nonsense mutation was confirmed. No frameshift mutations were found in *blaZ* allotypes.

Allelic variability of *blaZ* regulatory genes

Based on the *blaZ* variability analysis, we selected 51 representative strains to further characterize the variability in the *blaZ* regulatory genes, *blaI* and *blaR1*. Some

Table 3 Characteristics of *bla* locus alleles

Gene	Allele No.	Frequency		SNP ^{c)}	Amino acid substitutions			
		MRSA ^{a)}	MSSA ^{b)}		Silent	Conservative	Missense	Nonsense
<i>blaZ</i>	1	0.43	0.21	0	0	0	0	0
	2	0.02	0	1	0	0	1	1
	3	0.07	0.04	9	4	2	2	0
	4	0.04	0	9	4	2	3	0
	5	0.06	0	7	2	2	3	0
	6	0.11	0.46	13	8	2	3	0
	7	0.02	0	12	6	2	4	0
	8	0.10	0.04	11	6	2	3	0
	9	0.07	0.08	20	9	2	7	0
	10	0.04	0.04	19	8	2	7	0
	11	0.06	0.04	24	11	3	8	0
	12	0	0.04	24	11	2	8	0
	13	0	0.04	12	7	2	3	0
<i>blaI</i>	1	0.33	0.45	0	0	0	0	0
	2	0.15	0.25	6	5	0	1	0
	3	0.19	0.15	1	0	0	1	0
	4	0.19	0.05	4	3	0	1	0
	5	0.04	0	7	5	0	2	0
	6	0.07	0	4	3	0	1	0
	7	0.04	0	5	4	0	1	0
	8	0	0.05	3	1	1	1	0
	9	0	0.05	1	0	0	1	0
<i>blaR1</i>	1	0.26	0.24	0	0	0	0	0
	2	0.07	0	19	9	4	6	0
	3	0.10	0	18	7	4	6	0
	4	0.07	0.06	35	15	9	10	0
	5	0.07	0.18	35	15	7	11	0
	6	0.07	0.12	17	6	4	6	0
	7	0.07	0.06	24	10	7	7	0
	8	0.03	0	33	12	6	12	0
	9	0.16	0	31	11	6	11	0
	10	0.13	0.24	32	12	6	11	0
	11	0	0.06	20	9	5	7	0
	12	0	0.06	34	16	6	10	0

a) The total number of MRSA strains whose *blaZ*, *blaI* and *blaR1* genes were analyzed is 54, 27 and 31, respectively.

b) The total number of MSSA strains whose *blaZ*, *blaI* and *blaR1* genes were analyzed is 24, 20 and 17, respectively.

c) For each allele, the SNP were counted taking as reference Tn552 *bla* sequences (allele 1).

of these strains failed in the amplification of one of the *blaZ* regulatory genes (see Tables 1 and 2).

Within the length of *blaI* region analyzed (351 nucleotides), we detected 13 unique SNP, which account for the nine *blaI* allotypes detected (see Tables 3 and 4). Four of the nine *blaI* allotypes were present in both MRSA and MSSA, while three *blaI* allotypes were found in MRSA strains only and two in MSSA only. The SID was higher for MRSA than for MSSA although not statistically significant (SID = 82.1, 95%CI 74.6-89.5 vs SID = 74.2, 95%CI 60.5-87.9, respectively) (Table 4). On average, each *blaI* allele has 3.4 SNP comparing to the

prototype *blaI* sequence of Tn552 (allele 1), and *blaI* alleles were on average more polymorphic for MRSA than for MSSA (3.9 vs 2.5 SNP per allele, respectively) - see Tables 3 and 4.

Within the length of *blaR1* region analyzed (498 nucleotides), we detected 65 unique SNP, which account for the 12 *blaR1* allotypes detected (see Tables 3 and 4). Six of the 12 *blaR1* allotypes were present in both MRSA and MSSA, while four *blaR1* allotypes were unique for MRSA strains and two were characteristic of MSSA strains. The SID values were virtually identical for both MRSA and MSSA (SID = 88.8, 95%CI 83.2-

Table 4 Comparative analysis of the allelic variation in *bla* locus for MRSA and MSSA strains

	No. isolates	No. alleles	Simpson's		Unique SNP	SNP/allele (average)	Mutations per allele (average)				dN/dS		
			ID	CI (95%)			Silent	Conserv.	Missense	Nonsense	Average	St. dev.	
MRSA	<i>blaZ</i>	54	11	79.2	69.6-88.8	41	11.4	5.3	1.7	3.7	0.1	0.21	0.11
	<i>blaI</i>	27	7	82.1	74.6-89.5	10	3.9	2.9	0	1.0	0	0.11	0.05
	<i>blaR1</i>	31	10	88.8	83.2-94.4	60	24.4	9.7	5.3	8.0	0	0.24	0.11
MSSA	<i>blaZ</i>	24	9	76.1	61.3-90.9	35	14.7	7.1	1.9	4.6	0	0.17	0.04
	<i>blaI</i>	20	6	74.2	60.5-87.9	9	2.5	1.5	0.2	0.8	0	0.08	0.03
	<i>blaR1</i>	17	8	88.2	81.2-95.3	61	24.6	10.4	5.5	7.8	0	0.24	0.10
All	<i>blaZ</i>	78	13	81.1	75.0-87.3	43	12.4	5.8	1.8	4.0	0.1	0.20	0.10
	<i>blaI</i>	47	9	78.4	71.0-85.9	13	3.4	2.3	0.1	1.0	0	0.10	0.04
	<i>blaR1</i>	48	12	88.5	84.0-93.0	65	24.8	10.2	5.3	8.1	0	0.25	0.10



ID, index of diversity; CI, confidence interval; SNP, single-nucleotide polymorphism; Conserv., conservative; St. dev., standard deviation

94.4 vs SID = 88.2, 95%CI 81.2-95.3, respectively) (Table 4). On average, each *blaR1* allele has 24.8 SNP comparing to the prototype *blaR1* sequence of Tn552 (allele 1), with no significant differences between MRSA and MSSA (24.4 and 24.6 SNP/allele, respectively) - see Tables 3 and 4.

In agreement with what was observed for the *blaZ* gene, the cluster trees of *blaI* and *blaR1* alleles found in our collections also showed no clustering according to MSSA/MRSA phenotype or genetic lineages (Figures 3 and 4). For those strains in which the alleles of the three genes were determined, we constructed a cluster tree with the concatenated sequences - see Figure 5. In spite

of the relatively low number of allelic profiles, there was still no clear clustering of *bla* allotypes according to MSSA/MRSA phenotype or lineage, as the same allelic profile was present in different genetic lineages (e.g. profile 8/4/9 present in clonal complexes 5, 8 and 45) and, the same genetic lineage was characterized by profiles from different branches (e.g. clonal cluster 8 characterized by profiles 8/4/9, 1/1/1, 3/3/6, etc.).

The BlaI and BlaR1 variabilities at the protein level in the MRSA and MSSA strains were evaluated by comparison of the deduced amino acid sequence of all alleles against the corresponding deduced amino acid sequences of Tn552 (see Tables 3 and 4).






Figure 3 Cluster tree of *blaI* gene allotypes found in the MRSA and MSSA collections. See Figure 2 legend for details.

Overall, the deduced amino acid sequences of the *blaI* alleles revealed on average 2.3 silent mutations, 0.1 conservative missense mutations and 1 non-conservative missense mutation per allotype. The deduced amino acid sequences of the *blaR1* alleles showed on average 10.2 silent mutations, 5.3 conservative missense mutations and 8.1 non-conservative missense mutations per allotype. None of the SNP detected within the *blaI* or *blaR1* resulted in non-sense or frameshift mutations.

Selection pressure acting on the *bla* locus

Based on the allelic data obtained, we computed the dN/dS ratios as estimates for the selective pressure acting on the *bla* locus. The dN/dS ratios were computed for all pairs of alleles differing more than 1%, in order to give an estimate of the allelic divergence, excluding the anomalous dN/dS ratios of those pairs being very similar. The average of the obtained dN/dS values and respective standard deviations are summarized in Table 4. The dN/dS values for the three genes in the MRSA, MSSA and MRSA/MSSA partitions were well below 1 (between 0.08 and 0.25 with standard deviations between 0.05 and 0.1), which suggests a negative or purifying selection acting on the *bla* locus. In agreement with the average number of SNP per allele, the dN/dS ratios were significantly higher for the *blaR1* gene (0.24 - 0.25) and lower for *mecl* (0.08 - 0.11).




Figure 4 Cluster tree of *blaR1* allotypes found in the MRSA and MSSA collections. See Figure 2 legend for details.




Figure 5 Cluster tree of the concatenated *blaZ-blaR1* sequences found in the MRSA and MSSA collections. See Figure 2 legend for details.

Discussion

The rationale for this study comes from several observations strongly suggesting a role of *bla* genes in the acquisition, stabilization and regulation of *meCA* gene, the central element of “broad-spectrum” β -lactam resistance characteristic of MRSA strains. The purpose of this study was to evaluate the allelic variability of the *bla* locus in a representative collection of international epidemic MRSA clones and also, for comparative purposes, in a diverse collection of MSSA strains, in an attempt to establish evolutionary correlations between *bla* allotypes and β -lactam resistance phenotypes (i.e. between MRSA and MSSA), *SCCmec* types (i.e. polymorphisms in the *meCA* regulatory locus) and/or genetic lineages.

MRSA lineages are much less diverse than MSSA lineages in terms of their genome content, a consequence of their more recent evolutionary history [19,20] and, apparently, also due to some “host barrier” to the *SCCmec* acquisition [13]. These differences in genetic background variability were well illustrated in our collections since the international MRSA collection comprised eight lineages as defined by MLST clonal complexes, whereas in the smaller and local MSSA collection 15 lineages were represented.

In contrast to the genetic background diversity, we could not detect significant differences between MSSA and MRSA in terms of the *bla* locus allelic variability. Actually, there were disparate subtle differences in terms of number of allotypes and number of point mutations per allotype: e.g. 11 vs 9 *blaZ* allotypes and 11.4 vs 14.7 SNP/allele in MRSA and MSSA, respectively. These subtle differences may reflect the more

ancient evolutionary history of MSSA or a selective pressure to improve the *bla* locus activity in these strains. That is to say, although fewer *bla* types have been retained by the natural selection in MSSA, on average, these allotypes seem to have accumulated more adaptive mutations, in comparison to MRSA strains. In particular for *blaZ*, for which differences in terms of number of alleles and SNP/allele were more significant, the presence of the alternative β -lactam resistance mechanism mediated by the *mecA* gene in MRSA strains might have allowed a release in the selective pressure to keep *blaZ* with optimal activity, in contrast to MSSA, which rely only on *blaZ*-mediated resistance to β -lactams.

No correlation could be established between *bla* allotypes and strain backgrounds, β -lactam resistance phenotypes, strain origin and/or isolation dates, indicating that *bla* genes have evolved independently from *S. aureus* clonal lineages. This is particularly striking for MRSA strains, which have a very strong clonal structure. These observations may be explained either by differences in evolutionary clock speeds between the genetic background and the *bla* locus or may result from the horizontal transfer of *bla* genes between different lineages, which are usually integrated in mobile elements (plasmids and composite transposons). Interestingly, based on the characterization of a collection of several staphylococcal species, Olsen *et al*, suggested that there is little exchange of *bla* genes between strains or species [14], which somehow contradicts our findings. In our study, the most parsimony explanation for the presence of the same *bla* type in different genetic lineages either MRSA or MSSA or the presence of several *bla* types in the same lineage, is indeed a high frequency for the horizontal transfer of *bla* genes across *S. aureus* clonal clusters.

In spite of the lack of evolutionary links between *bla* allotypes and genetic lineages, our data strongly suggests a selective pressure to keep the *bla* locus fully functional, as illustrated by the calculated average dN/dS values well below 1. This observation is valid even on MRSA for which one could expect the accumulation of nonsense or frameshift mutations that would render the *bla* locus non-functional, due to presence of the *mecA* gene. Actually, the majority of the mutational events detected in this study were either silent or neutral mutations, being the *blaR1* the gene with the highest mutational rate and the *blaI* the one with the lowest. The increased allelic variability detected for *blaR1* (in terms of number of alleles, Simpson's index of diversity, average SNP/allele, and dN/dS values) may suggest that this sensor-inducer gene is the primary target for the evolutionary adaptive mechanisms in the *bla* locus, presumably to improve the induction efficiency of *blaZ*

expression or even *mecA* expression, in the case of MRSA strains with no functional *mecI-mecR1* regulatory system. In contrast, the relatively lower variability of the much smaller *blaI* gene, may suggest a fine-tuned repressor activity and a selective pressure to maintain the repressor activity; i.e to maintain the *blaZ* expression inducible.

Despite the cross-resistance to virtually all β -lactam antibiotics provided by *mecA*, most contemporary MRSA strains still carry, besides the SCC*mec* element, the β -lactamase locus. This might be due to the fact that not enough time has elapsed since the *mecA* acquisition for MRSA strains start losing the *bla* genes, because there is a little or no fitness cost associated to the *bla* genes, or because these genes may be linked to other positively selected genes (e.g. the cadmium resistance genes present in some β -lactamase plasmids). Alternatively, the *bla* locus may be involved in the "domestication" of the *mecA* gene, as *bla* genes have been shown to stabilize the *in vitro* *mecA* acquisition [12,13] and efficiently control *mecA* transcription [9,10], explaining the "retention" of a functional *bla* regulatory system by most contemporary MRSA strains [8]. Interestingly, as no correlation could be established between *bla* allotypes and SCC*mec* types, which have polymorphisms in the *mecA* regulatory locus, this maintenance of functional *blaI-blaR1* genes seems to be independent of the functional status of the *mecA* "natural" regulators *mecI-mecR1*.

Concerning the maintenance of a functional *blaZ* gene in MRSA strains one can speculate that, even in the presence of *mecA*, it might be useful for the bacteria to keep *blaZ* as a "first-line defense" against β -lactams. In fact, first generation β -lactams (i.e. penicillins) are still widely prescribed either empirically or for the treatment of specific infections (e.g. streptococcal infections). Moreover, penicillins have also been widely used prophylactically in the livestock industry. This means that, both in the nosocomial and community settings, MRSA are still exposed to penicillins and, under these circumstances, expression of β -lactamase is enough for survival under antibiotic pressure. From a physiological perspective, this ability to choose between the expression of two resistance genes may be advantageous for the bacteria since the expression of β -lactamase is likely to impose a smaller fitness cost than the expression of PBP2a. In fact, besides being much smaller than PBP2a (257 vs 668 amino acids), BlaZ is a secreted enzyme whereas PBP2a is a transpeptidase protein, which must be incorporated into the complex cell-wall metabolism.

Conclusion

In this study we have evaluated the allelic variation of the *bla* locus in MRSA and MSSA clinical strains. Although

no correlation between *bla* allotypes and genetic lineages, SCC*mec* types and β -lactam resistance phenotypes could be established, we provided evidence for the existence of a selective pressure to maintain the *bla* system fully functional even on MRSA strains and that the sensor-inducer gene *blaR1* is the primary target for the accumulation of adaptive mutations in the *bla* locus.

Acknowledgements

We thank T. Ito, D.C. Coleman, R. Daum, K.T. Park, W.B. Grubb, and A. Tomasz for having kindly given some of the prototype and reference strains used in this study. We thank J. Almeida for the assistance on the numerical data analysis.

Partial support for this study was provided by Projects POCI/BIA-MIC/60320/2004 and PTDC/BIA-MIC/64071/2006 from Fundação para a Ciência e Tecnologia (FCT), Lisbon, Portugal awarded to D.C. Oliveira and Project TROCAR, Contract number HEALTH-F3-2008-223031 from the European Commission awarded to H. de Lencastre. C. Milheiro was supported by grant SFRH/BPD/63992/2009 from FCT.

Author details

¹Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa (ITQB/UNL), Oeiras, Portugal. ²CREM, Department of Life Sciences, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa (FCT/UNL), Caparica, Portugal. ³CENTRIA, Department of Informatics, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa. ⁴Laboratory of Microbiology, The Rockefeller University, New York, NY, USA.

Authors' contributions

CM participated in the study design, carried out experimental work, analyzed and interpreted data and wrote the manuscript. AP carried out experimental work and analyzed data. LK analyzed and interpreted data. HdL participated in study design and corrected the manuscript. DCO conceived the study, participated in the study design, interpreted the data and wrote the manuscript. All authors have read and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 4 January 2011 Accepted: 15 April 2011

Published: 15 April 2011

References

1. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, et al: Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *Jama* 2007, **298**(15):1763-1771.
2. Chambers HF: The changing epidemiology of *Staphylococcus aureus*? *Emerg Infect Dis* 2001, **7**(2):178-182.
3. Furuya EY, Lowy FD: Antimicrobial-resistant bacteria in the community setting. *Nat Rev Microbiol* 2006, **4**(1):36-45.
4. de Lencastre H, Oliveira D, Tomasz A: Antibiotic resistant *Staphylococcus aureus*: a paradigm of adaptive power. *Curr Opin Microbiol* 2007, **10**(5):428-435.
5. Wilke MS, Lovering AL, Strynadka NC: Beta-lactam antibiotic resistance: a current structural perspective. *Curr Opin Microbiol* 2005, **8**(5):525-533.
6. Barber M, Rozwadowska-Dowzenko M: Infection by penicillin-resistant *Staphylococci*. *Lancet* 1948, **2**(6530):641-644.
7. Hartman B, Tomasz A: Altered penicillin-binding proteins in methicillin-resistant strains of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1981, **19**(5):726-735.
8. Livermore DM: Beta-Lactamases in Laboratory and Clinical Resistance. *Clin Microbiol Rev* 1995, **8**(4):557-584.
9. Hackbarth CJ, Chambers HF: *blaI* and *blaR1* regulate beta-lactamase and PBP2a production in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1993, **37**(5):1144-1149.
10. Ryffel C, Kayser FH, Berger-Bachi B: Correlation between regulation of *mecA* transcription and expression of methicillin resistance in *Staphylococci*. *Antimicrob Agents Chemother* 1992, **36**(1):25-31.
11. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC): Classification of staphylococcal cassette chromosome *mec* (SCC*mec*): guidelines for reporting novel SCC*mec* elements. *Antimicrob Agents Chemother* 2009, **53**(12):4961-4967.
12. Cohen S, Sweeney HM: Effect of the prophage and penicillinase plasmid of the recipient strain upon the transduction and the stability of methicillin resistance in *Staphylococcus aureus*. *J Bacteriol* 1973, **116**(2):803-811.
13. Katayama Y, Zhang HZ, Hong D, Chambers HF: Jumping the barrier to beta-lactam resistance in *Staphylococcus aureus*. *J Bacteriol* 2003, **185**(18):5465-5472.
14. Olsen JE, Christensen H, Aarestrup FM: Diversity and evolution of *blaZ* from *Staphylococcus aureus* and coagulase-negative staphylococci. *J Antimicrob Chemother* 2006, **57**(3):450-460.
15. Ambler RP: The structure of beta-lactamases. *Philos Trans R Soc Lond B Biol Sci* 1980, **289**(1036):321-331.
16. Richmond MH: Wild-Type Variants of Exopenicillinase from *Staphylococcus aureus*. *Biochem J* 1965, **94**:584-593.
17. East AK, Dyke KG: Cloning and sequence determination of six *Staphylococcus aureus* beta-lactamases and their expression in *Escherichia coli* and *Staphylococcus aureus*. *J Gen Microbiol* 1989, **135**(4):1001-1015.
18. Ito T, Katayama Y, Hiramatsu K: Cloning and nucleotide sequence determination of the entire *mec* DNA of pre-methicillin-resistant *Staphylococcus aureus* N315. *Antimicrob Agents Chemother* 1999, **43**(6):1449-1458.
19. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG: The evolutionary history of methicillin-resistant *Staphylococcus aureus* (MRSA). *Proc Natl Acad Sci USA* 2002, **99**(11):7687-7692.
20. Oliveira DC, Tomasz A, de Lencastre H: Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*. *Lancet Infect Dis* 2002, **2**(3):180-189.
21. Katayama Y, Robinson DA, Enright MC, Chambers HF: Genetic background affects stability of *mecA* in *Staphylococcus aureus*. *J Clin Microbiol* 2005, **43**(5):2380-2383.
22. Nubel U, Roumagnac P, Feldkamp M, Song JH, Ko KS, Huang YC, Coombs G, Ip M, Westh H, Skov R, et al: Frequent emergence and limited geographic dispersal of methicillin-resistant *Staphylococcus aureus*. *Proc Natl Acad Sci USA* 2008, **105**(37):14130-14135.
23. Smyth DS, McDougal LK, Gran FW, Manoharan A, Enright MC, Song JH, de Lencastre H, Robinson DA: Population structure of a hybrid clonal group of methicillin-resistant *Staphylococcus aureus*, ST239-MRSA-III. *PLoS One* 2010, **5**(1):e8582.
24. Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, Chantratita N, Gardete S, Tavares A, Day N, Lindsay JA, et al: Evolution of MRSA during hospital transmission and intercontinental spread. *Science* 2010, **327**(5964):469-474.
25. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. *Mol Biol Evol* 2007, **24**(8):1596-1599.
26. Grundmann H, Hori S, Tanner G: Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. *J Clin Microbiol* 2001, **39**(11):4190-4192.
27. Simpson EH: Measurement of diversity. *Nature* 1949, **163**:688-688.
28. Posada D, Buckley TR: Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests. *Syst Biol* 2004, **53**(5):793-808.
29. Zhang Z, Li J, Zhao XQ, Wang J, Wong GK, Yu J: KaKs_Calculator: calculating Ka and Ks through model selection and model averaging. *Genomics Proteomics Bioinformatics* 2006, **4**(4):259-263.
30. Oliveira DC, Tomasz A, de Lencastre H: The evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*: identification of two ancestral genetic backgrounds and the associated *mec* elements. *Microb Drug Resist* 2001, **7**(4):349-361.
31. de Lencastre H, Chung M, Westh H: Archaic strains of methicillin-resistant *Staphylococcus aureus*: molecular and microbiological properties of isolates from the 1960s in Denmark. *Microb Drug Resist* 2000, **6**(1):1-10.

32. Sanches IS, Ramirez M, Troni H, Abecassis M, Padua M, Tomasz A, de Lencastre H: Evidence for the geographic spread of a methicillin-resistant *Staphylococcus aureus* clone between Portugal and Spain. *J Clin Microbiol* 1995, **33**(5):1243-1246.
33. Roberts RB, Tennenberg AM, Eisner W, Hargrave J, Drusin LM, Yurt R, Kreiswirth BN: Outbreak in a New York City teaching hospital burn center caused by the Iberian epidemic clone of MRSA. *Microb Drug Resist* 1998, **4**(3):175-183.
34. Kreiswirth B, Kornblum J, Arbeit RD, Eisner W, Maslow JN, McGeer A, Low DE, Novick RP: Evidence for a clonal origin of methicillin resistance in *Staphylococcus aureus*. *Science* 1993, **259**(5092):227-230.
35. Dominguez MA, de Lencastre H, Linares J, Tomasz A: Spread and maintenance of a dominant methicillin-resistant *Staphylococcus aureus* (MRSA) clone during an outbreak of MRSA disease in a Spanish hospital. *J Clin Microbiol* 1994, **32**(9):2081-2087.
36. Dubin DT, Chikramane SG, Inglis B, Matthews PR, Stewart PR: Physical mapping of the *mec* region of an Australian methicillin-resistant *Staphylococcus aureus* lineage and a closely related American strain. *J Gen Microbiol* 1992, **138**(3):657.
37. Teixeira LA, Resende CA, Ormonde LR, Rosenbaum R, Figueiredo AM, de Lencastre H, Tomasz A: Geographic spread of epidemic multiresistant *Staphylococcus aureus* clone in Brazil. *J Clin Microbiol* 1995, **33**(9):2400-2404.
38. de Lencastre H, Severina EP, Milch H, Thege MK, Tomasz A: Wide geographic distribution of a unique methicillin-resistant *Staphylococcus aureus* clone in Hungarian hospitals. *Clin Microbiol Infect* 1997, **3**(3):289-296.
39. Milheiro C, Oliveira DC, de Lencastre H: Multiplex PCR strategy for subtyping the staphylococcal cassette chromosome *mec* type IV in methicillin-resistant *Staphylococcus aureus*: 'SCCmec IV multiplex'. *J Antimicrob Chemother* 2007, **60**(1):42-48.
40. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC: Pulsed-field gel electrophoresis typing of oxacillin-resistant *Staphylococcus aureus* isolates from the United States: establishing a national database. *J Clin Microbiol* 2003, **41**(11):5113-5120.
41. Roberts RB, de Lencastre A, Eisner W, Severina EP, Shopsis B, Kreiswirth BN, Tomasz A: Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in 12 New York hospitals. MRSA Collaborative Study Group. *J Infect Dis* 1998, **178**(1):164-171.
42. Shore A, Rossney AS, Keane CT, Enright MC, Coleman DC: Seven novel variants of the staphylococcal chromosomal cassette *mec* in methicillin-resistant *Staphylococcus aureus* isolates from Ireland. *Antimicrob Agents Chemother* 2005, **49**(5):2070-2083.
43. Aires de Sousa M, de Lencastre H: Evolution of sporadic isolates of methicillin-resistant *Staphylococcus aureus* (MRSA) in hospitals and their similarities to isolates of community-acquired MRSA. *J Clin Microbiol* 2003, **41**(8):3806-3815.
44. Cookson B, HARMONY participants: HARMONY - The International Union of Microbiology Societies' European Staphylococcal Typing Network. *Eurosurveillance* 2008, **13**(19):Article 4 [http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18860].
45. Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, Daum RS, Hiramatsu K: Novel type of staphylococcal cassette chromosome *mec* identified in community-acquired methicillin-resistant *Staphylococcus aureus* strains. *Antimicrob Agents Chemother* 2002, **46**(4):1147-1152.
46. Milheiro C, Oliveira DC, de Lencastre H: Update to the multiplex PCR strategy for assignment of *mec* element types in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2007, **51**(9):3374-3377.
47. Oliveira DC, Milheiro C, Vinga S, de Lencastre H: Assessment of allelic variation in the *ccrAB* locus in methicillin-resistant *Staphylococcus aureus* clones. *J Antimicrob Chemother* 2006, **58**(1):23-30.
48. Aires de Sousa M, de Lencastre H, Santos Sanches I, Kikuchi K, Totsuka K, Tomasz A: Similarity of antibiotic resistance patterns and molecular typing properties of methicillin-resistant *Staphylococcus aureus* isolates widely spread in hospitals in New York City and in a hospital in Tokyo, Japan. *Microb Drug Resist* 2000, **6**(3):253-258.
49. de Lencastre H, Severina EP, Roberts RB, Kreiswirth BN, Tomasz A: Testing the efficacy of a molecular surveillance network: methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecium* (VREF) genotypes in six hospitals in the metropolitan New York City area. The BARG Initiative Pilot Study Group. Bacterial Antibiotic Resistance Group. *Microb Drug Resist* 1996, **2**(3):343-351.
50. de Lencastre H, de Lencastre A, Tomasz A: Methicillin-resistant *Staphylococcus aureus* isolates recovered from a New York City hospital: analysis by molecular fingerprinting techniques. *J Clin Microbiol* 1996, **34**(9):2121-2124.
51. Sa-Leao R, Santos Sanches I, Dias D, Peres I, Barros RM, de Lencastre H: Detection of an archaic clone of *Staphylococcus aureus* with low-level resistance to methicillin in a pediatric hospital in Portugal and in international samples: relics of a formerly widely disseminated strain? *J Clin Microbiol* 1999, **37**(6):1913-1920.
52. Adcock PM, Pastor P, Medley F, Patterson JE, Murphy TV: Methicillin-resistant *Staphylococcus aureus* in two child care centers. *J Infect Dis* 1998, **178**(2):577-580.
53. Ma XX, Ito T, Chongtrakool P, Hiramatsu K: Predominance of clones carrying Panton-Valentine leukocidin genes among methicillin-resistant *Staphylococcus aureus* strains isolated in Japanese hospitals from 1979 to 1985. *J Clin Microbiol* 2006, **44**(12):4515-4527.
54. Kwon NH, Park KT, Moon JS, Jung WK, Kim SH, Kim JM, Hong SK, Koo HC, Joo YS, Park YH: Staphylococcal cassette chromosome *mec* (SCCmec) characterization and molecular analysis for methicillin-resistant *Staphylococcus aureus* and novel SCCmec subtype IVg isolated from bovine milk in Korea. *J Antimicrob Chemother* 2005, **56**(4):624-632.
55. Gomes AR, Sanches IS, Aires de Sousa M, Castaneda E, de Lencastre H: Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in Colombian hospitals: dominance of a single unique multidrug-resistant clone. *Microb Drug Resist* 2001, **7**(1):23-32.
56. Oliveira DC, Milheiro C, de Lencastre H: Redefining a structural variant of staphylococcal cassette chromosome *mec*, SCCmec type VI. *Antimicrob Agents Chemother* 2006, **50**(10):3457-3459.
57. Faria NA, Oliveira DC, Westh H, Monnet DL, Larsen AR, Skov R, de Lencastre H: Epidemiology of emerging methicillin-resistant *Staphylococcus aureus* (MRSA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection. *J Clin Microbiol* 2005, **43**(4):1836-1842.
58. Amorim ML, Faria NA, Oliveira DC, Vasconcelos C, Cabeda JC, Mendes AC, Calado E, Castro AP, Ramos MH, Amorim JM, et al: Changes in the clonal nature and antibiotic resistance profiles of methicillin-resistant *Staphylococcus aureus* isolates associated with spread of the EMRSA-15 clone in a tertiary care Portuguese hospital. *J Clin Microbiol* 2007, **45**(9):2881-2888.
59. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K: Novel type V staphylococcal cassette chromosome *mec* driven by a novel cassette chromosome recombinase, *ccrC*. *Antimicrob Agents Chemother* 2004, **48**(7):2637-2651.
60. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, et al: Genome and virulence determinants of high virulence community-acquired MRSA. *Lancet* 2002, **359**(9320):1819-1827.
61. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P, Reverdy ME, Enright MC, Vandenesch F, Etienne J: Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant *Staphylococcus aureus*, 2006. *Emerg Infect Dis* 2007, **13**(4):594-600.
62. Aires de Sousa M, Conceicao T, Simas C, de Lencastre H: Comparison of genetic backgrounds of methicillin-resistant and -susceptible *Staphylococcus aureus* isolates from Portuguese hospitals and the community. *J Clin Microbiol* 2005, **43**(10):5150-5157.

doi:10.1186/1471-2180-11-76

Cite this article as: Milheiro et al: Evidence for a purifying selection acting on the β -lactamase locus in epidemic clones of methicillin-resistant *Staphylococcus aureus*. *BMC Microbiology* 2011 **11**:76.